Penumbra Inc (NYSE:PEN)
$ 186.94 -13.07 (-6.53%) Market Cap: 7.26 Bil Enterprise Value: 7.66 Bil PE Ratio: 549.82 PB Ratio: 6.25 GF Score: 82/100

Penumbra Inc at JPMorgan Healthcare Conference Transcript

Jan 08, 2024 / 04:15PM GMT
Release Date Price: $247.32 (+6.69%)
Robert Justin Marcus
JPMorgan Chase & Co, Research Division - Analyst

Good morning, everyone. I'm Robbie Marcus, the Medtech analyst at JPMorgan. Thanks, everyone, for joining the 2024 JPMorgan Healthcare Conference. Very happy to have our next presenter Adam Elsesser, the CEO will be speaking for Penumbra. Adam?

Adam Elsesser
Penumbra, Inc. - Co-Founder, Chairman, President & CEO

Good morning. It's great to be here at this year's 42nd Annual JPMorgan Healthcare Conference. And of course, I want to thank Robbie for inviting us and your coverage of Penumbra. That's our safe harbor statement.

Penumbra is a healthcare company focusing on interventional products that treat a variety of medical conditions throughout the body. We're best known for our thrombectomy business. We're moving blood clots from head to toe. We started the company in 2004 and currently have approximately 4,000 employees worldwide. We're headquartered in Alameda, right across the bay from here and we manufacture all of our products in California.

Our revenue

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot